Chun-Lin Chen got B.S. (1983) and M.S. (1986) from China Pharmaceutical University. During 1986-1991, Chun-Lin Chen worked as Assistant Professor in China Pharmaceutical University. In 1994, Dr. Chen got Ph.D. in Pharmacology and Toxicology from Oklahoma State University and then he obtained postdoctoral training in Pharmaceutical Department of St. Jude Children’s Research Hospital. During 1997-2002, Dr. Chen served as Director of Pharmaceutical Department at Parker Hughes Cancer Center, Parker Hughes Institute, St. Paul, USA. In 2002, Dr. Chen joined Vertex Pharmaceuticals as a Staff Investigator at Department of Pharmacokinetics and Metabolism, Non-clinical Drug Evaluation Division, Vertex Pharmaceuticals Incorporated, Cambridge, USA.

Dr. Chen was the founder and CEO of Medicilon Inc. Medicilon has grown into one of the top drug discovery service companies in China. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Now Medicilon has the largest AAALAC-certified animal research facility in Shanghai complementing 3 technology platforms, including structural biology, non-human primate experimental lab and isotope lab. The company has built a fully integrated drug discovery research and development technology platform to provide high quality preclinical and IND filing services to CFDA and US FDA since year 2004. Medicilon strive to improve services to satisfy their global clients’ needs.

In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacological Society, Committee Member for Pharmacokinetics and Drug Metabolism Section of Chinese Pharmacological Society and Adjunct Professor for China Pharmaceutical University. Dr. Chen has been served as governmental funding reviewer for drug discovery programs in various Hi-Tech Parks including Xiamen, Wuhan and Shanghai. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University, Excellent returnee award and 1000 Plan Award from Chinese government.